Literature DB >> 8540654

The tumor biology of melanoma nodal metastases.

G Miliotes1, J Albertini, C Berman, R Heller, J Messina, F Glass, W Cruse, D Rapaport, C Puleo, N Fenske, C Petsoglou, R Deconti, G Lyman, D Reintgen.   

Abstract

Approximately 20 per cent of melanomas greater than 0.76 mm in thickness will metastasize to the regional lymph nodes if treated with wide local excision alone (WLE). Elective lymph node dissection (ELND) is associated with significant morbidity, which includes lymphedema, wound complications, and paresthesias of the extremity. An alternative operative approach uses selective lymphadenectomy with the identification of the sentinel node, defined as the first node in the lymphatic basin that drains the primary cutaneous site. This study consisted of 132 patients with melanomas greater than 0.76 mm. One hundred nine patients (83%) had histologic negative sentinel nodes, and 23 patients (17%) had one or more sentinel nodes positive for disease. In patients with metastatic disease, 30/35 (86%) sentinel nodes were positive, and 25/357 (7%) nonsentinel nodes were positive (P < 0.001). In 18 patients (78%) of the 23 patients with metastatic disease, the sentinel node was the only node positive, strongly suggesting that there is an orderly progression of metastases. Two patients developed metastatic nodal disease after removal of a negative sentinel node (false negative rate = 1.5). The mean follow-up was 1 year. Sentinel node histology reflects the histology of the remainder of the nodes in the lymphatic basin and "skip" metastases, defined as a negative sentinel node but positive nodes higher in the regional chain positive for metastases or an axillary recurrence after a negative sentinel node biopsy, are rare for malignant melanoma. Harvesting the sentinel node in patients with intermediate or greater thickness melanoma will, therefore, identify a subset of patients with metastatic disease who have the most to benefit from a complete node dissection. This surgical approach allows for complete pathological staging and therapeutic management of patients while significantly reducing expense and overall morbidity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8540654

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  5 in total

Review 1.  Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Authors:  Sabran J Masoud; Jennifer A Perone; Norma E Farrow; Paul J Mosca; Douglas S Tyler; Georgia M Beasley
Journal:  Curr Treat Options Oncol       Date:  2018-09-19

2.  Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.

Authors:  Kelly M McMasters; Michael E Egger; Michael J Edwards; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; Robert C G Martin; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; B Scott Davidson; Jeffrey E Gershenwald; Lee J Hagendoorn; Arnold J Stromberg; Charles R Scoggins
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

Review 3.  Recent advances in the care of the patient with malignant melanoma.

Authors:  D Reintgen; C M Balch; J Kirkwood; M Ross
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

Review 4.  Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials.

Authors:  Mark B Faries; Dale Han; Michael Reintgen; Lauren Kerivan; Douglas Reintgen; Corrado Caracò
Journal:  Clin Exp Metastasis       Date:  2018-05-18       Impact factor: 5.150

5.  Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.

Authors:  Vinod B Shidham; Dan Qi; R Nagarjun Rao; Scott M Acker; Chung-Che Chang; Bal Kampalath; Glen Dawson; Jinobya K Machhi; Richard A Komorowski
Journal:  BMC Cancer       Date:  2003-05-07       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.